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The aim of this study was to design a high
density multiepitope protein, which can be
a promising multiepitope vaccine candidate
against Hepatitis E virus (HEV). Initially, con-
served and antigenic helper T-lymphocyte
(HTL) epitopes in the HEV capsid protein were
predicted by in silico analysis. Subsequently, a
multiepitope comprising four HTL epitopes
with high-affinity binding to the HLA molecules
was designed, and repeated four times as high
density multiepitope construct. This construct
was synthesized and cloned into pET-30a (þ)
vector. Then, it was transformed and ex-
pressed in Escherichia coli BL21 cells. The high
density multiepitope protein was purified by
Ni-NTA agarose and concentrated using Ami-
con filters. Finally, the immunological proper-
ties of this high density multiepitope protein
were evaluated in vitro. The results showed
that the high density multiepitope construct
was successfully expressed and purified. SDS-
PAGE and Western blot analyses showed the
presence of a high density multiepitope protein
band of approximately 33 kDa. Approximately
1mg of the purified protein was obtained
from each liter of the culture media. Moreover,
the purified multiepitope protein was capable
of induction of proliferation responses, IFN-g
ELISPOT responses and IFN-g and IL-12 cyto-
kines production in a significant level in
peripheral blood mononuclear cells (PBMCs)
isolated from HEV-recovered individuals com-
pared to the control group. In conclusion,
the newly produced multiepitope protein can
induce significant T helper type 1 responses in
vitro, and can be considered as a novel strate-
gy for the development of HEV vaccines in the
future. J. Med. Virol.
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INTRODUCTION
Hepatitis E virus (HEV) is a positive-stranded RNA
virus which has been classified as the member of the
genus Hepevirus in the family Hepeviridae [Yama-
shita et al., 2009]. At least four major HEV genotypes
have been identified, which have different geographi-
cal distributions and host ranges [Xing et al., 2011].
Despite classification into four geographically distinct
genotypes, the HEV strains antigenically belong to a
single serotype and share cross-reacting epitopes due
to the high degree of sequence conservation [Wang
and Zhuang, 2004; Xing et al., 2011]. Genotype 1
includes most of human HEV strains which is
endemic in Asia and North Africa, genotype 2 is
identified in human and includes the Mexican strain
and few strains of African countries. Genotypes 3 and
4 have been identified in pigs and other animals;
however, humans can be infected with these two
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genotypes too. Genotype 3 predominates in industri-
alized countries, and genotype 4 is endemic in Asia,
particularly China, Taiwan, and Japan [Emerson and
Purcell, 2001; Yamashita et al., 2009].
HEV causes acute hepatitis in one-third of the
world’s population [Zhu et al., 2010], with mortality
rate of 1–15% in the general population [Xing et al.,
2011]. However, sporadic and epidemic outbreaks of
the acute hepatitis usually lead to a self-limited
disease, but the infection is potentially fatal and
causes fulminant hepatitis in susceptible individuals
such as pregnant women and patients with underly-
ing liver disease [Zhu et al., 2010; Xing et al., 2011],
and has high mortality rate of up to 30% among
pregnant women [Xing et al., 2011]. Therefore HEV
is a significant public health problem worldwide
especially in endemic areas and primary prevention
of the HEV infection seems essential.
Currently, no protective vaccine against HEV infec-
tion has been licensed and primary prevention re-
mains limited [Wang and Zhuang, 2004].
Development of an effective vaccine, which can
significantly reduce the prevalence of this disease, is
a desirable goal. Killed and live attenuated vaccines
are not available due to the lack of a permissive cell
culture system for HEV replication [Emerson and
Purcell, 2001]. Therefore the main focus for vaccine
design is on molecular approaches, especially expres-
sion of viral proteins in different expression systems
[Emerson and Purcell, 2001; Jimenez de Oya et al.,
2012].
The HEV genome (7.2 kb) contains three partial-
ly overlapping open reading frames (ORFs), includ-
ing ORF1, ORF2 and ORF3 [Zhou et al., 2004;
Jimenez de Oya et al., 2012]. ORF2, which encodes
capsid protein, is highly conserved and immunogenic
among HEV species [Emerson and Purcell, 2001].
Due to hydrophobicity and insolubility of full-length
capsid protein (72 kDa) [Tsarev et al., 1994; Zhang
et al., 2001], new generation vaccines such as multi-
epitope vaccines are of particular interest. Therefore,
the present study was undertaken to design a high
density multiepitope protein compromising four
HTL epitopes with high-affinity binding to the
HLA molecules using the in silico analysis, and to
evaluate the immunological properties of this protein
in vitro. Overall, this study represents a novel
strategy for the development of HEV vaccines in the
future.
MATERIALS AND METHODS
Rational Design of a High Density Multiepitope
Construct From HEV ORF2 Protein
The amino acid sequences of the ORF2 from Stan-
dard strains of HEV genotype 1 including Pakistan/
Sar-55 strain (accession number P33426), China strain
(accession number Q81871), Burma strain (accession
number P29326), Myanmar strain (accession number
Q04611) and India strain (accession number Q68985)
were obtained from Uniprot Knowledgebase (www.
uniprot.org). The sequences were aligned by MEGA
software version 4.0 (Biodesign Institute, Tempe, AZ)
[Tamura et al., 2007], and then the conserved sequen-
ces among these Strandard strains were determined.
The highly conserved HEV-derived HLA-DR-restricted
HTL epitopes of these strains were predicted by
SYFPEITHI online software (http://www.syfpeithi.de/
home.htm). HLA-DR binding affinity of the predicted
epitopes was determined by IEDB Analysis Resource
online program (http://tools.immuneepitope.org/ana-
lyze/html/mhc_II_binding.html). Genetic diversity of
MHC molecules is very high in human population;
therefore HTL epitopes with high population coverage
are needed for this study. Four epitopes with high-
affinity to the most common HLA-DR alleles in Iran
and world population were selected. Therefore it is
predicted that this construct could cover the most
world population. The four HTL epitopes (15 amino
acids) derived from HEV capsid protein including
HLA-DRB11501 (A150–164), HLA-DRB10701
(B320–334), HLA-DRB11101 (C370–384), HLA-
DRB10401 and HLA-DRB30101 (DR52) (D491–505)-
restricted epitopes were binded to each other as a
linear multiepitope (ABCD). To avoid creation of
junctional epitopes, the construct was designed with
amino acid spacer sequences (Gly–Pro–Gly–Pro–Gly)
between sequential HTL epitopes [Livingston et al.,
2002; Depla et al., 2008]. The four times repeated
multiepitope was constructed as high density multi-
epitope (Fig. 1A). Based on E. coli codon usage, the
nucleotide sequence of the high density multiepitope
gene was optimized using GenScript Rare Codon
Analysis Tool (GenScript, Piscataway, NJ) for efficient
expression. In order to simplify the purification of the
target protein, a sequence encoding 8-His tag was
added at the C-terminal of the optimized gene followed
by adding two stop codons (TAA and TAG) to termi-
nate protein synthesis. Two restriction-enzyme diges-
tion sites, NdeI and XhoI, were placed in the both ends
of the codon-optimized gene to subclone it into the
pET30a (þ) vector.
NdeI digestion site (CATATG) with starting codon
(ATG) was inserted at the N-terminal of the construct.
The XhoI digestion site (CTCGAG) was inserted at the
C-terminal of the construct after the second termina-
tion codon. In silico digestion was performed using
Clone Manager Basic software version 9 (Sci-Ed Soft-
ware, Cary, NC), and was checked by Vector NTI
software (Invitrogen, Carlsbad, CA). Finally, the opti-
mized high density multiepitope sequence was synthe-
sized and cloned into the commercial cloning vector,
pBluescript II SK (þ) by Biomatik Company (Biomatik
Corporation, Cambridge, Canada).
Subcloning and Construction of the
Recombinant Plasmid
Both pBluescript II SK (þ) vector carrying the high
density multiepitope gene (pBluescript II SK-high
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density multiepitope) and the pET-30a (þ) plasmid
(Novagen, Madison, WI) were digested by NdeI and
XhoI restriction enzymes (New England BioLab,
Ipswich, MA). After ligation by T4 DNA ligase (New
England BioLab, Ipswich, MA), the recombinant
plasmid pET30a-high density multiepitope was gen-
erated and transformed into E. coli DH5a competent
cells (Novagen) by electroporation [Chassy et al.,
1988]. The subcloning was confirmed by colony PCR,
restriction-enzyme digestion, and DNA sequencing.
The recombinant plasmid was then transformed into
competent E. coli BL21 (DE3) cells to enhance
protein expression (Novagen).
Protein Expression and Purification
E. coli BL21 (DE3) cells containing the recombi-
nant plasmid were cultured overnight, then inoculat-
ed in Terrific Broth (HiMedia, Mumbai, India)
supplemented with kanamycin (50mg/L) in a 1:100
volumetric ratio, and grown with shaking at 250 rpm
at 37˚C until the optical density at 600nm (OD 600)
reached 0.5. The bacterial culture was induced by
adding various concentrations of IPTG (0.1–1mM)
(Sigma–Aldrich, St. Louis, MO), and grown with
shaking for different induction times (2, 4, 6, 8, and
16hr) at different induction temperatures (37˚C,
30˚C, and 25˚C) to determine the optimal conditions
of protein expression. After the large-scale protein
expression, the target protein was purified by Ni-
NTA (Qiagen, Hilden, Germany) under denaturing
conditions using 8M urea [Taherkhani et al., 2014].
The purified protein was dialyzed in PBS containing
10% glycerol with a linear urea gradient of 6, 4, and
2M at 4˚C for 8hr in order to decrease the amount of
urea, and concentrated using Amicon Ultra-4 Centrif-
ugal Filter Unit (EMD Millipore, Billerica, MA). SDS-
PAGE and Western blot were performed to confirm
the presence of the target protein [Laemmli, 1970;
Hao et al., 2013; Taherkhani et al., 2014]. Concentra-
tion of the protein was measured by the Bradford
method [Bradford, 1976]. To remove bacterial
Fig. 1. A: Schematic presentation of high density multiepitope construct. The amino acid
sequence of four HTL epitopes from HEV capsid protein and GPGPG amino acid spacers
between them in the high density multiepitope construct are presented. B: Schematic
presentation of truncated ORF2 (aa 112–608).
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endotoxin contamination in the purified protein,
Toxin Eraser Endotoxin Removal kit was used
according to the manufacturer procedure (GenScript).
Truncated ORF2 Protein
The truncated ORF2 protein (aa 112–608) of HEV
strain sar-55 (Fig. 1B) was expressed in E. coli BL21
host cells using the recombinant plasmid pET-30a-
ORF2 (aa 112–608) and purified by Ni-NTA (Qiagen)
as described previously [Taherkhani et al., 2014].
Study Patients
This protocol was approved by the ethical commit-
tee of Ahvaz Jundishapur University of Medical
Science. A statement on Ethical Committee approval
and the informed consent was taken from all partic-
ipants. Ten recovered individuals from acute hepati-
tis E infection (6 males and 4 females; mean
ageSD, 40.30 13.76 years) with positive anti-HEV
IgG antibody were enrolled in this study. The control
group consisted of 12 healthy individuals (7 males
and 5 females; mean ageSD, 38.08 15.35 years)
with no history of acute hepatitis, and with negative
anti-HEV IgM/IgG antibodies. The commercial ELISA
kits (HEV IgG and HEV IgM ELISA kits, DIA.PRO,
Milan, Italy) were used for all the participants. All
the participants were negative for hepatitis B surface
antigen, anti-HAV IgM antibody and anti-HCV anti-
bodies (HBs Ag ELISA kit, HAV IgM ELISA kit,
HCV Ab ELISA kit, DIA.PRO) with normal ALT
level.
Separation of Peripheral Blood
Mononuclear Cells
Peripheral blood mononuclear cells (PBMCs) of the
each individual were isolated from 10ml heparinized
venous blood by density gradient centrifugation using
Ficoll-Hypaque (Lymphoflot, Biotest, Dreieich,
Germany). The isolated PBMCs were washed and
resuspended in complete RPMI 1640 medium (Invi-
trogen). The viability of the cells was assessed by
Trypan blue staining.
Cell Proliferation Assay Using Non-Radioactive
MTT Assay
The cell proliferation assay was performed using
non-radioactive MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide) assay [Majumdar
et al., 2013]. In brief, approximately 1 105 cells/well
of PBMCs of each sample in RPMI 1640 and 10%
FCS were added to four wells of round-bottom 96-well
plates in total volume of 180ml/well, stimulated with
20ml/well of truncated ORF2 protein (10mg/ml), high
density multiepitope (10mg/ml) and Phytohemaggluti-
nin (PHA) (5mg/ml) (Sigma–Aldrich) separately, and
incubated at 37˚C for 4 days. The unstimulated well
of each sample was used as negative control. RPMI
1640 (20ml) was used as blank. After 4 days, 10ml of
MTT solution (5mg/ml) was added to each well and
incubated at 37˚C for 4hr. Then, 100ml of isopropanol
containing 0.04N HCl was added to each well and
mixed thoroughly. Finally, the absorbance of the wells
was read at 570nm with a reference wavelength of
630nm by an ELISA reader (Tecan Sunrise ELISA
Reader; Tecan Trading AG, Mannedorf, Switzerland).
The results were showed as proliferation index (PI),




The ELISPOT assay for HEV-specific IFN-g-secret-
ing cells was carried out by Human IFN-g ELISPOT
Ready-SET-Go kit (eBioscience, San Diego, CA) ac-
cording to manufacturer’s protocol. Briefly, a 96-well
PVDF bottomed ELISPOT plate (Millipore, Bedford,
MA) was coated with 100ml/well of Capture Antibody
solution and incubated overnight at 4˚C. Approxi-
mately 2 105 cells/well of PBMCs of each sample
suspended in RPMI 1640 and 10% FCS along with
10mg/ml high density multiepitope protein and 10mg/
ml truncated ORF-2 protein separately were added to
2 wells in total volume of 150ml/well. For negative
control unstimulated PBMCs was used. For positive
control, 5mg/ml of PHA (Sigma–Aldrich) was used.
After 24-hr incubation at 37˚C, cells and medium
were decanted from the plate and the plate was
washed three times with ELISPOT Wash Buffer.
100ml of Biotinylated Detection Antibody was added
to each well and incubated overnight at 4˚C. After
incubation, the plate was emptied and washed as
described above. 100ml/well of Avidin–Horseradish
Peroxidase reagent was added, and the plates were
incubated at room temperature for 45min. After
incubation, the plates were washed three times with
ELISPOT wash buffer and two times with 1X PBS;
then, 100ml/well of freshly prepared AEC (3-amino-9-
ethyl carbazole) substrate solution (Sigma–Aldrich)
was added to the wells and incubated at room
temperature until dark purple spots appears. The
reaction was stopped by washing wells three times
with 200ml/well distilled water. Plate was air-dried
and the number of IFN-g–producing cells in each
well was counted by a dissection stereoscope (Nikon,
Tokyo, Japan) and expressed as spot-forming cells
(SFCs) per 105 cells.
Cytokine Assay
At a concentration of 1 105 cells/well, PBMCs of
each sample in RPMI 1640 and 10% FCS were added
to the four wells of 96-well plates, and stimulated
with truncated ORF2 protein (10mg/ml), high density
multiepitope protein (10mg/ml), and PHA (5mg/ml)
separately at 37˚C. The unstimulated PBMCs of each
sample were used to evaluate spontaneous production
of cytokines. Culture supernatants were collected
after 48hr (24hr for IL-12). Levels of four cytokines
J. Med. Virol. DOI 10.1002/jmv
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(IL-12 p70, IFN-g, IL-4 and IL-10) were measured in
duplicate by commercial ELISA kits (eBioscience)
according to the manufacturer’s instructions. The
ELISA results were expressed as picograms per
milliliter (pg/ml).
Statistical Analysis
Statistical analysis was performed using SPSS 17
software (SPSS, Chicago, IL) and P values of less
than 0.05 were considered statistically significant.
Discrete variables were compared using the Pearson’s
chi-square test or fisher’s exact test. Intergroup
comparisons (recovereds vs. controls) were performed
using Independent T Test or Mann–Whitney U test.
Intragroup comparisons (High density multiepitope
versus ORF2) were made by Paired T Test or
Wilcoxon test. All data were presented as meanSE.
RESULTS
Preparation of High Density Multiepitope
Protein
The high expression of the protein was induced by
IPTG at a final concentration of 1mM at 30˚C for
4 hr. SDS-PAGE and Western blotting analysis of the
resultant protein showed a protein band of approxi-
mately 33 kDa corresponding to high density multi-
epitope (Fig. 2). Approximately 1mg of purified
protein was obtained from each liter of culture
media.
Cell Proliferative Responses to High Density
Multiepitope Protein and Truncated
ORF2 Protein
The cell proliferative responses in HEV-recovered
group following stimulation with high density multi-
epitope protein and truncated ORF2 protein were
found higher than control group (P< 0.001); and
these responses were observed higher with high
density multiepitope protein than truncated ORF2
protein in HEV-recovered group (P¼ 0.013) (Table I,
Fig. 3).
IFN-g ELISPOT Responses to High Desity
Multiepitope Protein and Truncated
ORF2 Protein
IFN-g ELISPOT responses to high density multi-
epitope protein and truncated ORF2 protein were
found significantly higher in HEV-recovered individu-
als than control group (P< 0.001). These responses to
high density multiepitope protein were observed
slightly higher than truncated ORF2 protein in HEV-
recovered group, with no significant observation
(P¼ 0.220). Table I and Figure 4 show the frequency
of IFN-g-secreting cells following stimulation with
high density multiepitope protein and truncated
Fig. 2. A: SDS-PAGE analysis of the expressed and purified
high density multiepitope protein in E. coli. The high density
multiepitope protein band is visualized at approximately 33kDa.
Lane 1, uninduced control; Lane 2, induction with 1mM IPTG
for 4hr; Lane 3, induction with 1mM IPTG for 8hr; Lane 4,5,
flow-through; Lane 6–8, washing steps of the Ni column; Lane
9–11, the first, the second, and the third purified eluates of high
density multiepitope protein from the Ni column; Lane 12,
prestained protein ladder (Cinagen, Tehran, Iran). B: Western
blot analysis of the expressed and purified high density multi-
epitope protein in E. coli. The high density multiepitope protein
band is visualized at approximately 33kDa. Lane 1, prestained
protein ladder (Cinagen); Lane 2, flow-through; Lane 3, wash;
Lane 4–7, the first, the second, the third, and the fourth eluates.
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ORF2 protein in HEV-recovered individuals and
control group.
HEV-Specific Cytokine Responses
The levels of IFN-g and IL-12 p70 responses to
truncated ORF2 protein and high density multiepi-
tope in the recovered group were found significantly
higher compared to control group (P< 0.001). Howev-
er, the levels of these stimulated cytokines with high
density multiepitope protein were found higher than
truncated ORF2 protein with no significant observa-
tion. The levels of specific IL-10 for high density
multiepitope protein and truncared ORF2 protein
were found moderate among the HEV-recovered
group, while the levels of specific IL-4 for the both
proteins were low (Table I, Fig. 5).
DISCUSSION
A better understanding of the HEV-specific cellular
immune responses may help us in designing and
development of vaccine for the prevention and control
of the HEV infection. Although some progress has
TABLE I. Levels of Cytokines, IFN-g ELISPOT, and Cell Proliferative Responses to High Density Multiepitope Protein
and Truncated ORF2 Protein in HEV-Recovered Individuals and Control Group.
IFN-g IL-12 IL-10 IL-4 ELISPOT Cell proliferation
Control group (n¼ 12)
Unstimulated 7.70 1.26 9.12 0.61 11.90 2.24 3.000.408 1.58 0.57
ORF2 14.28 1.84 17.07 2.63 19.16 2.77 4.630.54 3.00 1.51 1.400.032
Multiepitope 15.63 1.67 18.08 2.14 17.08 2.92 4.790.41 2.00 0.55 1.300.038
PHA 408.08 14.76 105.58 8.50 205.50 30.45 11.561.36 215 29.76 2.800.087
Recovered group (n¼10)
Unstimulated 11.82 2.01 12.50 2.17 16.30 3.19 3.200.37 2.20 0.77
ORF2 136.86 17.46 106.70 13.41 24.80 6.58 5.310.54 58.90 18.31 1.900.057
Multiepitope 142.70 16.21 115.40 16.71 25.30 5.23 4.110.38 63.00 16.96 2.200.063
PHA 415.70 22.59 100.60 8.91 197.40 32.45 10.901.29 226.80 41.0 2.700.063
P-value 0.114 (NS) 0.742 (NS) 0.177 (NS) 0.824 (NS) 0.811 (NS) 0.074 (NS)
P-value 0.132 (NS) 0.335 (NS) 0.839 (NS) 0.127 (NS) 0.220 (NS) 0.013
P-value <0.001 <0.001 0.446 (NS) 0.395 (NS) <0.001 <0.001
P-value <0.001 <0.001 0.168 (NS) 0.251 (NS) <0.001 <0.001
The levels of cytokines are presented as picograms per milliliter (pg/ml), the results of ELISPOT assay are expressed as spot forming cells
per 105 cells (SFC/105 cells), the results of cell proliferation assay are shown as proliferation index (PI).
All Data are shown as meanSE.
NS¼non-significant.
ORF2 vs. high density multiepitope in control group.
ORF2 vs. high density multiepitope in recovered group.
Recovered vs. control regarding ORF2.
Recovered vs. control regarding high density multiepitope.
Fig. 3. Cell proliferative responses to high density multi-
epitope protein and truncated ORF2 protein in HEV-recovered
individuals and control group. The results are shown as mean
SE PI (proliferation index). Black (&) and hatched ( ) bars
represent control group and HEV-recovered group, respectively.
Fig. 4. IFN-g ELISPOT responses to high desity multiepitope
protein and truncated ORF2 protein in HEV-recovered and
control groups. Data are presented as spot forming cells per
105 cells (SFC/105 cells). Black (&) and hatched ( ) bars repre-
sent control group and HEV-recovered group, respectively.
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been achieved in developing HEV vaccine, but due to
some limitations in current approach for vaccine
preparation such as the duration of the response and
cost effectiveness of vaccine, the attempt was made to
develop an alternative HEV vaccine [Jimenez de Oya
et al., 2012].
The virus-specific T-helper cell immune responses
have been shown to be essential for controlling and
clearing viral infection by activating cytotoxic T cells
and producing cytokines especially INF-g which can
suppress viral replication. Thus, viral proteins com-
prising helper T-lymphocyte (HTL) epitopes may be
useful as protective vaccines [Aggarwal et al., 2007].
It has been shown that HEV capsid protein has
several immunogenic epitopes [Gu et al., 2004]. Shata
et al. identified dominant and subdominant epitopes
of HEV capsid protein such as amino acids 271–286,
199–214, 463–478, 583–598, and 631–646 [Shata
et al., 2007]. Aggarwal et al. mapped CD4 T-cell
epitopes in HEV ORF2 protein, and found the
immunodominant T-cell epitopes of capside protein
are encompassed amino acids 73–156, 289–444, and
505–588 [Aggarwal et al., 2007]. Khudyakov et al.
reported the antigenic regions in HEV ORF2 protein
Fig. 5. The levels of IFN–g (A), IL–12 p70 (B), IL–10 (C), and IL–4 (D) responses to
truncated ORF2 protein and high density multiepitope protein in HEV-recovered and control
groups. Data are presented as picograms per milliliter (pg/ml). Black (&) and hatched ( ) bars
represent control group and HEV-recovered group, respectively.
J. Med. Virol. DOI 10.1002/jmv
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are encompassed amino acids 319–340, 631–648, and
641–660 [Khudyakov et al., 1993]. Selection of the
epitopes is the most important part of the design of
the epitope-based vaccines that can guarantee the
effectiveness and extent of the desired immune
responses.
This study focused on the consereved epitopes with
high-affinity binding to the different HLA molecules
to cover the majority of the human population, on
this basis the multiepitope protein comprising these
epitopes was constructed. This multiepitope design is
a new strategy and may counter the limitations
present in current vaccine against HEV, but it
requires further investigation. To date, no application
of multiple HLA-DR-restricted epitopes was reported
to induse HTL responses against HEV infection.
Oany et al. designed a multiepitope vaccine candidate
compromising B cell and T cell epitopes from spike
protein of human coronavirus by in silico analysis. In
their study, sequences of the spike proteins were
collected from the UniProtKB database and the
consereved epitopes with high-affinity binding to the
different HLA molecules were predicted using in
silico tools to cover the majority of the world popula-
tion. This computational design was a novel study to
determine antigenic epitopes in spike protein and to
design an epitope-based vaccine against human coro-
navirus [Oany et al., 2014].
These type of vaccines were reported to have many
advantages including the stability, lack of carcinogen-
ic, large scale production with the least equipments,
no need for cold chain storage, the ability to stimulate
the immune system against a wide variety of strains
and genotypes of a microorganism, and use in differ-
ent races or high population coverage [Elliott et al.,
1999; Livingston et al., 2002; Sette and Fikes, 2003;
Jackson et al., 2006]. Meanwhile, some disadvantages
like the creation of junctional epitopes in the sequen-
tial arrangement of the epitopes have limited using
these constructs [Livingston et al., 2002; Depla et al.,
2008]. Junctional epitopes is created by the juxtaposi-
tion of two epitopes, and can suppress the immune
responses to the main epitopes [Livingston et al.,
2002]. This problem was overcome through applica-
tion of the spacer residues between the epitopes to
improve appropriate epitope processing. Furthermore,
it has been reported that if the epitope is expressed
with high density will enhance protective immunity
[Liu et al., 2004; Lu et al., 2008]. Lu et al. designed
constructs consisting of various V3 epitope densities
from HIV-1 gp120, and found that high epitope
density in one single protein molecule could enhance
protective immunity [Lu et al., 2008]. Liu et al.
reported that high epitope density from M2 protein of
influenza virus enhanced specific humoral immunity
against flu virus [Liu et al., 2004].
Vaccine development is dependent not only on
selecting antigens and epitopes but also on defining
the immune responses against target epitopes. By
evaluating the antigenicity and immunogenicity of
the high density multiepitope protein, it was indicat-
ed that the high density multiepitope protein stim-
ulates slightly stronger T helper cell responses
compared to truncated ORF2 protein. It has been
shown that during acute infection, virus-specific T
helper cell responses can clear viral infection but lack
of its activity leads to chronic infection [MacDonald
et al., 2002]. In this study, the HLA typing was not
carried out and the frequencies of various HLA
alleles among the participants were not determined.
So it is not clear which type of HLA alleles among
the HEV-recovered individuals had a low or high-
affinity HLA binding epitopes against the multiepi-
tope protein.
Li et al. designed a multiepitope construct compris-
ing six low-affinity HIV gag and pol CTL epitopes
restricted to HLA-A0201 and the HIV p24 antigen
by bioinformatics analysis. They used cryptic epitope
modification to enhance the immunogenicity of low-
affinity HLA-A2.1-binding epitpes, and found the
multiepitope can induce a strong CD8þ T cell im-
mune responses in mice [Li et al., 2013b]. Jafarpour
et al. designed and synthesized a multiepitope con-
struct encoding conserved and immunogenic epitopes
from HIV-1 tat, pol, gag, and env proteins by
bioinformatics analyses as a new DNA vaccine candi-
date. The designed multiepitope plasmid was able to
induce proper immune responces in BALB/c mice
[Jafarpour et al., 2014]. Li et al. designed a multi-
epitope construct encoding T and B lymphocyte
epitopes from latent membrane protein 2 (LMP2) of
Epstein–Barr virus (EBV) based on mammalian
codon usage. The recombinant plasmid pcDNA3.1þ/
EBV-LMP2 multiepitope was constructed and trans-
fected into COS-7 cells. This multiepitope plasmid
DNA was able to stimulate strong cellular and
humoral immunity in mice [Li et al., 2013a].
In the present study, high level of specific IFN-g
and IL-12 responses (T helper type 1 cytokines) and
low level of IL-10 and very low level of IL-4 responses
(T helper type 2 cytokines) against high density
multiepitope protein and truncated ORF2 protein
were observed among the HEV-recovered individuals.
Thus, both proteins can be considered as promising
vaccine candidate against HEV infection. Hashish
et al. designed a multiepitope fusion protein
compromising two B cell and T cell epitopes from the
E2 glycoprotein of bovine viral diarrhea virus
(BVDV), and also K99 major subunit FanC and STa
toxoid of Enterotoxigenic Escherichia coli (ETEC). In
their study, FanC-STa-E2 gene construction was
cloned into the expression vector pET28 and trans-
formed into E. coli BL21 cells. FanC-STa-E2 fusion
protein was well expressed by IPTG-induction (1mM)
at 37˚C for 4 hr and purified by Ni-NTA agarose
using His-tag. This multiepitope fusion protein could
develop neutralizing antibodies against ETEC and
BVDV in vitro [Hashish et al., 2013].
Beside vaccine development, multiepitope techno-
logy can be used for diagnosis. Several studies have
J. Med. Virol. DOI 10.1002/jmv
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been performed on multiepitopes proteins for develop-
ment of diagnostic kit. The results of these studies
showed that the use of multiepitope proteins can
increase the sensitivity and specificity of the tests,
since this kind of proteins has great efficiency to
expose conserved and immunodominant epitopes
[Dipti et al., 2006; de Souza et al., 2013]. de Souza
et al. designed a high density multiepitope protein
containing three copies of four conserved epitopes
from hepatitis B core protein (HBcAg), and developed
an ELISA using this recombinant protein. The devel-
oped ELISA was useful for hepatitis B diagnosis [de
Souza et al., 2013]. Dipti et al. designed a novel
recombinant multiepitope protein comprising six con-
served and immunodominant epitopes from hepatitis
C virus, and developed an anti-HCV diagnostic kit
using this protein. The multiepitope protein was able
to detect anti-HCV antibodies in human plasma with
high degree of sensitivity and specificity [Dipti et al.,
2006].
Although several microorganisms and cell lines are
currently used for expression of foreign genes, but
still E. coli are routinely used for expression of target
proteins [Vincentelli and Romier, 2013]. Fast cultiva-
tion, well-known genetics and high-level expression
capabilities with high purity are some other advan-
tages of E. coli expression system [Fakruddin et al.,
2013]. Despite all these advantages, expression of a
foreign gene in E. coli may be hampered by the
presence of rare codons and high GC contents within
the gene-coding region which result in decrease of the
expression level or production of insoluble and non-
functional proteins [Mondal et al., 2013; Elena et al.,
2014]. In the present study, E. coli BL21 cell was
used for expression of the high density multiepitope
protein. The target genes were cloned in to the
pET30aþ plasmid and expressed by IPTG-induction
under control of strong bacteriophage T7 promoter
and T7 RNA polymerase of the E. coli BL21 cell. The
IPTG-induction is economically desirable method and
increases protein production [Mondal et al., 2013].
Previous studies have reported high yield protein
purification by Ni2þ chelate affinity chromatography
using His-tag [Glynou et al., 2003; Farshadpour et al.,
2014]. The application of affinity tags is simple, rapid,
cost effective and also efficient for purification of
proteins, and also has no effect on the structure,
folding and function of the protein [Glynou et al.,
2003; Carson et al., 2007]. In the present study, His-
tag was used for the purification. The results of this
study show that E. coli is a good system for expres-
sion of recombinant proteins with high yield.
In conclusion, a high density multiepitope protein
capable of induction of T helper type 1 responses was
successfully produced and evaluated in vitro. The
results of this study provide much information for
the design of HEV multiepitope vaccine. However,
further works will be needed to evaluate protective
immune response of the high density multiepitope
protein in vivo.
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